A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorNovo Nordisk A/S
About this trial
The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.
Eligibility criteria
Qualifiers
Male or female
Age 18-55 years (both inclusive) at the time of signing the informed consent.
Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator.
Disqualifiers
Known or suspected hypersensitivity to study intervention(s) or related products.
Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimole per mole (mmol/mol)] at screening.
Trial design
Treatments tested in this trial
- NNC0113-5840
- Placebo
Treatment groups
48 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov